Tools   Select Another Resource Report Type

http://www.enzolifesciences.com/

An Antibody supplier

Proper citation: Enzo Life Sciences (RRID:SCR_003900) Copy   

•   Source: SciCrunch Registry
  

https://github.com/nornir/

A set of Python software packages that takes large sets of overlapping images in 2D and 3D and produces registered (aligned) 3D volumes at any size and scale. These tools were originally designed to construct 3D connectomics volumes from terabytes of image data for the Marc lab at the University of Utah Moran Eye Center.

Proper citation: Nornir (RRID:SCR_003585) Copy   

•   Source: SciCrunch Registry
  

https://github.com/jamesra/nornir-buildmanager/wiki

Software package that constructs 2D and 3D datasets from 2D image mosaics using the nornir tools. This produces a set of images and transforms on disk which can be accessed via Viking, HTTP, or written as a stack of images.

Proper citation: nornir-buildmanager (RRID:SCR_003584) Copy   

•   Source: SciCrunch Registry
  

http://www.knossostool.org/

Software tool for the visualization and annotation of 3D image data and was developed for the rapid reconstruction of neural morphology and connectivity. By dynamically loading only data from the surround of the current view point, seamless navigation is not limited to datasets that fit into the available RAM but works with much larger dataset stored in a special format on disk. Currently, KNOSSOS is limited to 8-bit data. In addition to viewing and navigating, KNOSSOS allows efficient manual neurite annotation (''skeletonization''). KNOSSOS is being used mostly for reconstructing cell morphologies from 3D electron microscopic data generated by Serial Block-Face Electron Microscopy (SBEM), with an occasional application to 2-photon and confocal optical microscopy data.

Proper citation: KNOSSOS (RRID:SCR_003582) Copy   

•   Source: SciCrunch Registry
  

http://www.primmbiotech.com/

An Antibody supplier

Proper citation: Primm Biotech (RRID:SCR_003809) Copy   

•   Source: SciCrunch Registry
  

http://www.alzheimer-europe.org/

A non-governmental organization aimed at raising awareness of all forms of dementia by creating a common European platform through co-ordination and co-operation between Alzheimer organizations throughout Europe. Alzheimer Europe is also a source of information on all aspects of dementia.

Proper citation: Alzheimer Europe (RRID:SCR_003802) Copy   

•   Source: SciCrunch Registry
  

http://neurovault.org/

Data repository where researchers can publicly store and share unthresholded statistical brain activation maps produced by MRI and PET studies.

Proper citation: NeuroVault (RRID:SCR_003806) Copy   

•   Source: SciCrunch Registry
  

http://neurostars.org

A question answering web site and forum that focuses on neuroinformatics and neuroscience. Initially conceived by Istvan Albert's highly successful BioStar website within the Bioinformatics community, NeuroStars is born as an experiment to engage the Neuroinformatics community after some unfruitful attempts in StackExchange's Area51. Posts that are detailed and specific, written clearly and simply are welcome.

Proper citation: NeuroStars (RRID:SCR_003805) Copy   

•   Source: SciCrunch Registry
  

http://www.webcitation.org/

An on-demand archiving system for webreferences (cited webpages and websites, or other kinds of Internet-accessible digital objects), which can be used by authors, editors, and publishers of scholarly papers and books, to ensure that cited webmaterial will remain available to readers in the future. Users make a local copy of the cited webpage / webmaterial and archive the cited URL to enable readers permanent access to the cited material. If cited webreferences in journal articles, books etc. are not archived, future readers may encounter a 404 File Not Found error when clicking on a cited URL. It's free and takes only 30 seconds. A WebCite-enhanced reference is a reference which contains - in addition to the original live URL (which can and probably will disappear in the future, or its content may change) - a link to an archived copy of the material, exactly as the citing author saw it when he accessed the cited material.

Proper citation: WebCite (RRID:SCR_003804) Copy   

•   Source: SciCrunch Registry
  

http://www.telethon.it/en

Since 1990 Telethon, along with millions of Italians, has stepped up to the challenge of beating muscular dystrophy and the other genetic diseases. It is a marathon against time, because there are many people who live with these rare disorders, and the resources to deal with them have to be carefully measured out because there is not much public or private funding invested in this field of research, and the path to finding cures is often long and tortuous. The foundation In order to guarantee as much research funding as possible into muscular dystrophy and other genetic diseases, the Telethon team works throughout the year and has adopted a management system for the donated funds that is strict and efficient. For every euro raised by Telethon, about eighty euro cents reach the cutting edge laboratories and excellent research centers. Scientific area The selection of the best research projects, the funding of dedicated researchers and the foundation and maintenance of its research institutes make Telethon a point of Italian excellence in the world. Along with recognition from the international scientific community, Telethon's world of research is the biggest ally of all the people who live with muscular dystrophy or other genetic disorders every day. The online database provides complete information about the projects funded by Telethon from 1991 to the present. The archive contains information about all the Foundation's efforts in the field of biomedical research. In addition to a search by disease, it is possible, using the advanced search function, to interrogate the database by groups of disorders, by the name of a researcher or research institute, or by the town, province, or region where projects are based. The use of another search filter makes it possible to check which research projects are ongoing and which have come to an end.

Proper citation: Telethon Foundation (RRID:SCR_003803) Copy   

•   Source: SciCrunch Registry
  

http://www.cimit.org/

A non-profit consortium of Boston academic medical centers and universities (and growing) to accelerate the healthcare innovation cycle by fostering interdisciplinary, inter-institutional collaboration among experts in translational research, medicine, science, engineering, healthcare implementation and entrepreneurship in concert with industry, foundations and government to rapidly improve patient care. It concentrates on early stage, high-risk ideas, projects and supports them through to a commercial exit from academia. It provides innovators with resources to explore, develop and implement novel technological solutions for today's most urgent healthcare problems. CIMIT is dedicated to helping develop medical technology that will help both military and civilian patients.

Proper citation: Center for Integration of Medicine and Innovative Technology (RRID:SCR_003710) Copy   

•   Source: SciCrunch Registry
  

http://www.atheroremo.org/

Project targeting vulnerable plaques causing unexpected acute myocardial infarcts and sudden cardiac deaths by identifying and validating novel drug targets as well as devising and validating diagnostic tests. It has been designed to advance the present knowledge on the role of inflammatory remodeling in the different stages of atherosclerosis. It will also provide important knowledge for the development of strategies for prevention and clinical management of vascular diseases.

Proper citation: AtheroRemo (RRID:SCR_003831) Copy   

•   Source: SciCrunch Registry
  

http://c3nproject.org/

Project designing, prototyping, optimizing, and evaluating a learning health system to improve clinical practice, patient self-management, and disease outcomes of patients with chronic illness. This open, peer production system combines the collective input of patients, clinicians and researchers. It combines large clinical data registries with patient entered data and makes them accessible and interactive. A platform allows researchers to design, test and implement new knowledge and innovations in patient care. To test their platform approach, C3N is working on a model of treating children with Inflammatory Bowel Disease using the ImproveCareNow Network of pediatric clinics. Following this demonstration phase, the goal is to apply the social, scientific and technical platform to transform the care of a variety of chronic illnesses. The C3N effort has the following goals: # Deploy and optimize an integrated set of engagement tools to make it easier for patients and care providers to collect and use the right information during the clinical encounter and in between visits. # Prototype novel interventions to re-design care delivery by promoting the development of tools for real-time and dynamic population management, "just-in time" scheduling of visits, virtual clinic visits, and measuring the impact of these interventions on health, care, and cost. # Pilot and deploy patient-focused technology to improve the flow of data between patients, clinicians and scientists to enable faster learning and improvement.

Proper citation: Collaborative Chronic Care Network (RRID:SCR_003708) Copy   

•   Source: SciCrunch Registry
  

http://www.remynd.com/

Organization that drives the development of disease-modifying treatments against Alzheimer's, Parkinson's, Diabetes and other protein misfolding disorders through two independently managed business units: * Contract Research: The in-vivo Contract Research Organization (CRO) helps its clients to assess the pharmacokinetics and -dynamics of their experimental treatments against Alzheimer's disease. The main focus is on efficacy testing of candidate drugs in reMYND's proprietary Alzheimer mouse models expressing the clinical APP-London allele as single transgene or in combination with clinical alleles of human PS1 and TAU. * Drug Discovery: The Drug Discovery and Development Unit (DDD) focuses on disease-modifying treatments against protein-misfolding disorders, such as Alzheimer's disease (tau), Parkinson's disease (-synuclein), and Diabetes. In addition, reMYND grants licenses and markets commercial kits of RadarScreen, a technology for rapid and cost-effective identification of genotoxic liabilities in early stage drug discovery. reMYND has been substantially supported by grants from IWT and from The Michael J Fox Foundation.

Proper citation: reMYND (RRID:SCR_003824) Copy   

•   Source: SciCrunch Registry
  

http://www.hybrigenics.com/

A bio-pharmaceutical company with a focus on research and development of new targets & therapies against proliferative diseases. Its current development program is based on inecalcitol, a vitamin D receptor agonist being studied in three potential indications: * alone in chronic lymphocytic leukaemia * in combination with imatinib in chronic myeloid leukaemia * in prostate cancer, for use with current standards of care Hybrigenics'' research program investigates the action of enzymes called Deubiquitinating Enzymes (DUBs) in the recycling of onco-proteins and the utility of proprietary patented DUB inhibitors against various cancer indications. Hybrigenics Services, a Hybrigenics subsidiary, markets very specialized scientific services to researchers in all areas of life sciences who want to identify, validate and inhibit protein interactions in animal, plant or microbiological cells.

Proper citation: Hybrigenics (RRID:SCR_003822) Copy   

•   Source: SciCrunch Registry
  

http://www.rochester.edu/

Private research university in Rochester, New York. University grants undergraduate and graduate degrees, including doctoral and professional degrees.

Proper citation: University of Rochester; New York; USA (RRID:SCR_003821) Copy   

•   Source: SciCrunch Registry
  

http://elementsofmorphology.nih.gov/

Data set of standardized terms used to describe human morphology including definitions of terms for the craniofacies in general, the major components of the face, and the hands and feet. This provides a uniform and internationally accepted terms to describe the human phenotype.

Proper citation: elements of morphology (RRID:SCR_003707) Copy   

•   Source: SciCrunch Registry
  

http://www.innomed-addneuromed.com/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 9,2023. Project portal for a cross European study designed to find biomarkers, or tests, for Alzheimer's disease. Its objectives are to produce and improve experimental models of Alzheimer's for biomarker discovery and to identify a biomarker for Alzheimer's disease suitable for diagnosis, prediction, and monitoring disease progression for use in clinical trials and in clinical practice. The baseline dataset database was scheduled to be completed and locked in 2008 and become available to researchers by 2009. Requests to access the data will be reviewed by the scientific projects committee.

Proper citation: AddNeuroMed (RRID:SCR_003819) Copy   

•   Source: SciCrunch Registry
  

http://www.mrc-cbu.cam.ac.uk/

Unit studying human cognition and the brain with about 90 researchers and postgraduate students investigating topics such as attention, emotion, language and memory. They are developing new treatments for depression, improving hearing through cochlear implants, and helping children to overcome memory problems. With a large collection of scientists engaged in both basic and translational research on the mind and brain, the Unit provides an exceptional training and academic environment that benefits postgraduate students and researchers at all levels. A significant part of their research makes use of brain imaging and they have excellent on-site facilities for magnetic resonance imaging (MRI) magnetoencephalography (MEG) and electroencephalography (EEG). They also have clinical facilities at Addenbrooke's Hospital. The Unit has close links both with the hospital and with Cambridge University.

Proper citation: MRC Cognition and Brain Sciences Unit (RRID:SCR_003818) Copy   

•   Source: SciCrunch Registry
  

http://www.ddmore.eu/mdl

A human writeable and human readable language to express the information required to describe pharmacometric models and tasks using these models. The specification of the MDL offers a standard for coding models and associated objects and defining how to execute tasks. The standards for defining MDL objects are independent of any specific target modelling software. This allows the user to specify the model in a consistent manner and facilitates understanding of the model and associated tasks, regardless of the software used to build the model. New modelling applications may take advantage of the standard without having to re-invent how to describe common modelling processes.

Proper citation: MDL (RRID:SCR_003816) Copy   

•   Source: SciCrunch Registry